The single most persistent mistake in peptide culture is the assumption that more, continuous, forever is how these compounds work. It is not. The serious research literature uses cycles for a reason. Receptor pharmacology, physiological tolerance, and the basic information-theory of biological signaling all push in the same direction: the dose is a message, and a message repeated without pause stops being heard.
This matters more for women than for men, because female endocrine physiology is already running on cycles. Superimposing a continuous pharmacological signal on a system built for pulsatile feedback produces a specific kind of noise that the literature is only beginning to map carefully.
What the research actually does
When you read the animal and early human studies on GH-axis peptides like CJC-1295 or ipamorelin, you almost never see continuous daily administration beyond twelve weeks. The studies are structured around protocols of four to ten weeks, followed by a washout period, followed by re-dosing. There is a reason for this. Receptor desensitization — the pituitary's downregulation of the signaling pathway when it's saturated — starts to reduce response if the signal is tonic. The pulse is the point.
The same is true for copper peptides, mitochondrial peptides, and most of the compounds in the broader research catalogue. GHK-Cu is studied in courses. MOTS-c is studied in courses. BPC-157 is studied most often in acute injury protocols, not as a lifetime supplement. The shape of the research is not a continuous line. It is a series of pulses separated by windows.
Why this is harder to sell
The subscription supplement industry is built on the opposite assumption: that you take the thing every day, forever, and the company ships it to you at an interval that makes the revenue graph go up and to the right. That model does not match peptide pharmacology.
Juno is built differently on purpose. Our subscription cadence is aligned with the research literature on each compound, not with what would maximize monthly frequency. A ten-week run, a four-week washout, an assessment window, another cycle if the research question is ongoing. The math of our retention is worse. The math of our correspondence with the literature is better.
How to think about cycles
The useful mental model is that you are running a structured protocol with a start, a middle, an end, and a review. You note what you are studying — recovery, sleep, skin, composition. You run the cycle. You pause. You read your own biology during the washout. Then you decide whether to re-dose or move to a different compound based on what you learned, not on what the inventory calendar says.
This is the difference between a research practice and a wellness subscription. One is trying to generate data. The other is trying to generate compliance.
"The subscription supplement industry is built on the assumption that you take the thing every day, forever. That model does not match peptide pharmacology."
What a Juno cycle looks like
For most of the GH-axis and repair compounds, a representative protocol from the literature looks like eight to ten weeks on, four weeks off, with a light-touch assessment during the washout. For GHK-Cu the research windows tend to be longer — twelve to sixteen weeks — because the tissue-remodeling outcome is slower to register. For mitochondrial peptides like MOTS-c the windows are shorter, because the metabolic endpoints shift faster.
None of this is medical advice. It is a summary of the dosing shapes you find in the peer-reviewed literature, condensed into a cadence that you, as a research-aware reader, can use as a starting point for your own reading.
The cadence is the practice. The compound is the tool.